Context Therapeutics Inc. (NASDAQ:CNTX) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Posted by Brian Himes on May 22nd, 2026

Shares of Context Therapeutics Inc. (NASDAQ:CNTX – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the eight analysts that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, six have given a buy rating and one has assigned a strong buy rating to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $6.60.

CNTX has been the subject of a number of analyst reports. Piper Sandler lifted their price target on Context Therapeutics from $4.00 to $7.00 and gave the company an “overweight” rating in a research note on Tuesday, March 24th. Weiss Ratings restated a “sell (d-)” rating on shares of Context Therapeutics in a research note on Monday, April 20th. Guggenheim restated a “buy” rating and issued a $5.00 target price on shares of Context Therapeutics in a research note on Tuesday, March 24th. D. Boral Capital restated a “buy” rating and issued a $9.00 target price on shares of Context Therapeutics in a research note on Tuesday, March 24th. Finally, Lifesci Capital upgraded Context Therapeutics to a “strong-buy” rating in a research note on Monday, February 23rd.

Check Out Our Latest Research Report on CNTX

Hedge Funds Weigh In On Context Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. Sanctuary Advisors LLC purchased a new position in shares of Context Therapeutics in the 1st quarter worth approximately $51,000. Virtu Financial LLC purchased a new position in shares of Context Therapeutics in the 4th quarter worth approximately $43,000. Quadrature Capital Ltd purchased a new position in shares of Context Therapeutics in the 4th quarter worth approximately $68,000. OMERS ADMINISTRATION Corp purchased a new position in shares of Context Therapeutics in the 1st quarter worth approximately $211,000. Finally, XTX Topco Ltd boosted its stake in shares of Context Therapeutics by 858.8% in the 4th quarter. XTX Topco Ltd now owns 101,605 shares of the company’s stock worth $149,000 after buying an additional 91,008 shares during the last quarter. Hedge funds and other institutional investors own 14.03% of the company’s stock.

Context Therapeutics Stock Performance

CNTX stock opened at $2.40 on Friday. The company has a market capitalization of $220.51 million, a P/E ratio of -5.71 and a beta of 1.57. Context Therapeutics has a 52-week low of $0.49 and a 52-week high of $3.62. The business has a 50-day simple moving average of $2.56 and a two-hundred day simple moving average of $1.98.

Context Therapeutics (NASDAQ:CNTX – Get Free Report) last released its quarterly earnings results on Wednesday, May 6th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.03. As a group, sell-side analysts forecast that Context Therapeutics will post -0.35 earnings per share for the current fiscal year.

About Context Therapeutics

(Get Free Report)

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.